Table 1.
Descriptors of the object drug cohorts.
| Object drug cohort | |||
|---|---|---|---|
| Clopidogrel | Pravastatin | ||
| Persons | 21,577 | 5,785 | |
| Days of observation, sum | 16,285,312 | 5,112,014 | |
| Days of observation, median (quartile 1–quartile 3) per person | 490 (183–1,089) | 758 (331–1,427) | |
| Gastrointestinal bleed/intracranial hemorrhage outcomes, sum | 32,839 | 8,575 | |
| Demographics | |||
| Age in years, median (quartile 1–quartile 3) | 73.7 (65.5–78.7) | 72.9 (65.1–78.8) | |
| Sex, sum (%) female | 10,125 (46.9) | 2,999 (51.8) | |
| Race, sum (%) | African American | 2,709 (12.6) | 788 (13.6) |
| Asian | 409 (1.9) | 117 (2.0) | |
| Caucasian | 15,075 (69.9) | 4,025 (69.6) | |
| Hispanic | 1,771 (8.2) | 440 (7.6) | |
| Unknown | 1,613 (7.5) | 415 (7.2) | |
| Dose covariate, time-varying | |||
| Object drug average daily dose (quartile 1–quartile 3), median, in milligrams | 75.0 (75.0–75.0) | 40.0 (20.0–40.0) | |
| Drug covariates, time-varying* | |||
| Anticoagulant, person-days (%) | 677,620 (4.2) | 514,442 (10.1) | |
| Aspirin, person-days (%) | 45,043 (0.3) | 32,489 (0.6) | |
| Cilostazol, person-days (%) | 138,014 (0.8) | 28,817 (0.6) | |
| Dipyridamole, person-days (%) | 21,138 (0.1) | 28,845 (0.6) | |
| Gastroprotective agent, person-days (%) | 4,129,210 (25.4) | 1,203,886 (23.6) | |
| Nonsteroidal anti-inflammatory drug, person-days (%) | 596,580 (3.7) | 209,489 (4.1) | |
| Disease covariates, time varying | |||
| Cerebrovascular disease†, person-days (%) | 9,856,287 (60.5) | 2,331,869 (45.6) | |
| Gastrointestinal bleed/intracranial hemorrhage‡, person-days (%) | 8,502,055 (52.2) | 2,766,370 (54.1) | |
| Ischemic heart disease†, person-days (%) | 13,541,836 (83.2) | 2,994,267 (58.6) | |
*
dispensed (pursuant to a prescription) on the day of observation or within the prior 30 days
†
diagnosis (any position, any claim type) on the day of observation or ever prior
‡
diagnosis (any position, any claim type) ever prior to the day of observation